Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart scan surprise: does a simple notification boost lifesaving treatment?

NCT ID NCT05858879

Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 233 people with heart or blood vessel disease who had calcium buildup in their heart arteries found by chance on a chest CT scan. Researchers wanted to see if telling both the patient and their doctor about this finding would encourage them to start cholesterol-lowering medication. The goal was to improve treatment rates in people who were not already on such therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

233 people

The number who actually took part.

Started

Oct 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 84 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Presence of CAC on non-gated chest CT scans performed from 2021 to 2025 2. Age \<85 years 3. Diagnosis of ASCVD(coronary artery disease, peripheral artery disease, or cerebrovascular disease) 4. Visit to Stanford affiliated clinician since 2022 at one of the following Stanford clinics including University affiliated clinics: 1. Internal Medicine 2. Family Medicine 3. Cardiology 4. Neurology 5. Vascular surgery 5. Primary language is English or Spanish Exclusion Criteria: 1. No diagnosis of ASCVD 2. Patients receiving lipid-lowering therapy 3. Dementia 4. Metastatic cancer or active cancer undergoing chemotherapy 5. Hospice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease coronary atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD Coronary artery calcification

Contacts and locations

Locations

  • Stanford University

    Stanford, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.